Claim check · Effectiveness
SS-31 and aging
Claim (representative wording, not a quotation): SS-31 (elamipretide) reverses or slows aging in people.
Plain-English answer
A single dose improved a short-lived muscle-energy measurement in older adults, but it did not improve fatigue resistance and the effect was gone a week later. That is not evidence that it slows aging.
Verdict: Overstated. Part of the claim is supported, but the claim says more than the sources show: a wider population, a stronger outcome, a human result from animal work, or a certainty the design cannot give.
Scope
- Population or organism
- 39 healthy adults aged 60 to 85 selected for poorly functioning muscle mitochondria
- Study design
- Randomized, double-blind, placebo-controlled, single-dose trial (phase 2) measuring muscle mitochondrial energetics by spectroscopy
- Boundary
- Short-term muscle mitochondrial capacity in older adults. Not lifespan, healthspan, disease or any aging endpoint, and not the approved Barth syndrome use.
Strongest evidence
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial (PLoS One, 2021; PMID 34264994) (Peer-reviewed paper)
Population or organism: 39 healthy older adults, 60 to 85 years, 46% female, enrolled for poorly functioning mitochondria
Design: Randomized, double-blind, placebo-controlled, single 2-hour infusion
Where in the source: Abstract, Results: change in maximal ATP production (ATPmax) P = 0.055 and percent change P = 0.045 immediately after infusion; no difference on day 7; no significant change in resting coupling; no significant effect on fatigue resistance.
MTP-131 (Bendavia) on skeletal muscle function in the elderly (NCT02245620) (Registry record)
Population or organism: 41 participants aged 60 to 85 (actual)
Design: Registered phase 2 trial, results posted 2020-06-23
Where in the source: Results tab, primary outcome measure: change from baseline in ATPmax, mean 0.17 (SD 0.196) for MTP-131 and 0.12 (SD 0.244) for placebo, at 2 hours after the start of infusion and day 7; no between-group analysis is posted.
Study of Healthy Aging and Physical Function With Elamipretide (NCT07275424) (Registry record)
Population or organism: 30 participants planned, age 65 and over
Design: Registered phase 2 trial, recruiting since 2025-11-26
Where in the source: Record header: status Recruiting; no results posted.
What remains uncertain
- The headline effect was borderline (P = 0.055 and 0.045 on two versions of the measure) in a small trial, and no primary-endpoint threshold is stated in the abstract WPF read.
- The registry's posted group values (41 participants) and the paper's analysis set (39) differ in size and are not the same analysis; WPF did not reconcile them.
- Mouse and cell studies of SS-31 in aging exist in the literature (80 PubMed records matched aging terms) but were not summarized here.
What would change the answer
- A longer randomized trial in older adults with a clinical or functional aging outcome (for example mobility, strength or frailty) showing a benefit that lasts after dosing.
- Posted results from NCT07275424 or similar trials.
Exact gaps
- No human trial of elamipretide with an aging, healthspan or lifespan outcome was found. The animal aging literature was counted but not read.
Where WPF looked for missing evidence
Searched on 2026-11-14 in: PubMed; ClinicalTrials.gov API v2.
- PubMed: (elamipretide OR SS-31 OR MTP-131 OR Bendavia) in title/abstract -> 473 records
- PubMed: the same terms AND (aging OR ageing OR older adults OR aged OR sarcopenia) -> 80 records
- PubMed: (elamipretide OR SS-31) AND (aging OR older) AND (randomized OR clinical trial) -> 4 records, one a human randomized trial in older adults (PMID 34264994)
- ClinicalTrials.gov: query.intr=elamipretide -> 25 registrations, two in older or healthy-aging populations (NCT02245620, NCT07275424)
Found: One completed randomized single-dose trial in older adults with a mitochondrial measure, and one registered healthy-aging trial that is still recruiting.
Not searched: Full text of the 80 aging-related PubMed records; Embase; Unregistered studies.
Not finding evidence in these searches is not proof that none exists.
Date checked and review status
Checked: · version 1.6.0
Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.
Related pages
Profiles: /directory/elamipretide
Research journeys: /research/journey/elamipretide
What changed?: /research/changes#trial_result_posted
Cite this check
The citation names the version and an address that keeps returning what was checked, even after a newer version is published.
SS-31 and aging: A single dose improved a short-lived muscle-energy measurement in older adults, but it did not improve fatigue resistance and the effect was gone a week later. That is not evidence that it slows aging. Verdict: Overstated. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim ss-31-slows-aging, checked 2026-11-14. AI-assisted source verification; human review none recorded.
Page:
https://www.worldpeptidefoundation.org/research/check/ss-31-slows-aging
Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/ss-31-slows-aging?version=1.6.0
Versioned record: /api/research/claims/ss-31-slows-aging?version=1.6.0